The kallikrein-kinin system (KKS) is an important endogenous pathway involved in a serial of physiological and pathological changes, such as blood pressure controlling and inflammation. It has been proved to exert a role in several disorders of central nerve system, including epilepsy. Studies of different animal models, including pilocarpine-indued, audiogenic kindling and amygdaloid kindling animal models, have showed that the expressions of the bradykinin receptors B1 and B2 were both up-regulated, or showed that the relative ratio of bradykinin receptor B1 to B2 was elevated. In patients with temporal lobe epilepsy and hippocampal sclerosis, the levels of bradykinin receptors B1 and B2 in pyramidal neurons and kallikrein 1 in astrocytes were all over-expressed in hippocampus. It has been suggested that bradykinin receptor B1 may be pro-convulsant while bradykinin receptor B2 may be linked to neuroprotection. The possible underlying mechanisms include promoting blood-brain-barrier disruption, inducing the release of excitatory amino acids, and mediating the inflammatory response. KKS may become a novel target for prevention and treatment of epilepsy. This paper summarizes the advances in research on KKS and epileptogenesis.
ZOU Jing, LU Qinchi.
Kallikrein-kinin system and epileptogenesis[J]. Journal of Neurology and Neurorehabilitation. 2016, 12(3): 152-156 https://doi.org/10.12022/jnnr.2016-0048
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] RODI D, COUTURE R, ONGALI B, et al. Targeting kinin receptors for the treatment of neurological diseases[J]. Curr Pharm Des, 2011, 11(10):1313-1326.
[2] COSTA-NETO C M, DILLENBURG-PILLA P, HEINRICH T A, et al. Participation of kallikrein-kinin system in different pathologies[J]. Int Immunopharmacol, 2008, 8(2):135-142.
[3] THORNTON E, ZIEBELL J M, LEONARD A V, et al. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury[J]. Molecules, 2010, 15(9):6598-6618.
[4] VIEL T A, BUCK H S. Kallikrein-kinin system mediated inflammation in Alzheimer’s disease in vivo[J]. Curr Alzheimer Res, 2011, 8(1):59-66.
[5] LACOSTE B, TONG X K, LAHJOUJI K, et al. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer’s disease mice[J]. J Neuroinflammation, 2013, 10:57.
[6] MAHABEER R, BHOOLA K D. Kallikrein and kinin receptor genes[J]. Pharmacol Ther, 2000, 88(1):77-89.
[7] CALIXTO J B, CABRINI D A, FERREIRA J, et al. Kinins in pain and inflammation[J]. Pain, 2000, 87(1):1-5.
[8] PHAGOO S B, POOLE S, LEEB-LUNDBERG L M. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts[J]. Mol Pharmacol, 1999, 56(2):325-333.
[9] LEEB-LUNDBERG L M, MARCEAU F, MüLLER-ESTERL W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanism to pathophysiological consequences[J]. Pharmacol Rev, 2005, 57(1):27-77.
[10] MARCEAU F, SABOURIN T, HOULE S, et al. Kinin receptors: functional aspects[J]. Int Immunopharmacol, 2002, 2(13-14):1729-1739.
[11] YU J, PRADO G N, TAYLOR L, et al. Hybrid formation between the intracellular faces of the bradykinin B2 and angiotensinⅡ AT1 receptors and signal transduction[J]. Int Immunopharmacol, 2002, 2(13-14):1807-1822.
[12] ONGALI B, CAMPOS MM, BREGOLA G, et al. Autoradiographic analysis of rat brain kinin B1 and B2 receptors: normal distribution and alterations by epilepsy[J]. J Comp Neurol, 2003, 461(4):506-519.
[13] ARGA?ARAZ G A, SILVA JR J A, PEROSA S R, et al. The synthesis and distribution of the kinin B1 and B2 receptors are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy[J]. Brain Res, 2004, 1006(1):114-125.
[14] PEREIRA M G, GITAí D L, PA?ó-LARSON M L, et al. Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy[J]. Int Immunopharmacol, 2008, 8(2):200-205.
[15] PEROSA S R, ARGA?ARAZ G A, GOTO E M, et al. Kinin B1 and B2 receptors are overexpressed in the hippocampus of humans with temporal lobe epilepsy[J]. Hippocampus, 2007, 17(1):26-33.
[16] SILVA JA J R, GOTO E M, PEROSA S M, et al. Kinin B1 receptors facilitate the development of temporal lobe epilepsy in mice[J]. Int Immunopharmacol, 2008, 8(2):197-199.
[17] ADOLFO ARGA?ARAZ G, REGINA PEROSA S, CRISTINA LENCIONI E, et al. Role of kinin B1 and B2 receptors in the development of pilocarpine model of epilepsy[J]. Brain Res, 2004, 1013(1):30-39.
[18] MARTINS A H, ALVES J M, PEREZ D, et al. Kinin-B2 receptor mediated neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists[J]. PLoS One, 2012, 7(2):e30755.
[19] RODI D, BUZZI A, BARBIERI M, et al. Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice[J]. Neuroscience, 2013, 248:392-402.
[20] WERNER F M, COVE?AS R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect?[J]. Epilepsy Behav, 2015. pii: S1525-5050(15)00045-1. doi:10.1016/j.yebeh.2015.01.038. [Epub ahead of print].
[21] WANG C, HONG Z, CHEN Y. Involvement of p38 MAPK in the drug resistance of refractory epilepsy through the regulation multidrug resistance-associated protein 1[J]. Neurochem Res, 2015, 40(7):1546-1553.
[22] NAFFAH-MAZZACORATTI MDA G, GOUVEIA T L, SIM?ES P S, et al. What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?[J]. World J Biol Chem, 2014, 5(2):130-140.
[23] BEIRITH A, SANTOS A R, CALIXTO J B. The role of neuropeptides and capsaicin-sensitive fibres in glutamate-induced nociception and paw oedema in mice[J]. Brain Res, 2003, 969(1-2):110-116.
[24] BREGOLA G, VARANI K, GESSI S, et al. Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy[J]. Neuroscience, 1999, 92(3):1043-1049.
[25] MAZZUFERI M, BINASCHI A, RODI D, et al. Induction of B1 bradykinin receptors in the kindled hippocampus increases extracellular glutamate levels: a microdialysis study[J]. Neuroscience, 2005, 135(3):979-986.
[26] PRAT A, BIERNACKI K, POULY S, et al. Kinin B1 receptor expression and function on human brain endothelial cells[J]. J Neuropathol Exp Neurol, 2010, 59(10):896-906.
[27] G?BEL K, PANKRATZ S, SCHNEIDER-HOHENDORF T, et al. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking[J]. J Autoimmun, 2011, 36(2):106-114.
[28] RASLAN F, SCHWARZ T, MEUTH S G, et al. Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood–brain barrier leakage and inflammation[J]. J Cereb Blood Flow Metab, 2010, 30(8):1477-1486.
[29] GUEVARA-LORA I, LABEDZ A, SKRZECZYNSKA-MONCZNIK J, et al. Bradykinin and des-Arg10-kallidin enhance the adhesion of polymorphonuclear leukocytes to extracellular matrix proteins and endothelial cells[J]. Cell Commun Adhes, 2011, 18(4):67-71.
